Hemeo raises €675,000 in an oversubscribed seed equity round

Hemeo Announces Successful Closure of First Equity Finance Round

Hemeo has successfully closed its first equity finance round, raising €675,000, which was substantially oversubscribed, underscoring strong investor interest in Hemeo's technology poised to revolutionize coagulation with data. The diverse group of (international) investors supporting Hemeo is a testament to their confidence in our mission.

The funds raised will facilitate the completion of development, regulatory approval, and launch of our initial application. This application will provide clinicians with a real-time interactive tool to manage bleeding and transfusions according to clinical guidelines. Crucially, it will also serve as a platform to develop and validate our AI technology for predictive modelling and personalized treatments.

Annually, over 5 million patients in Europe and the US are affected by serious bleeding or thrombosis, leading to high mortality and morbidity rates. Founded in 2019 with AI technology rooted in 15 years of research at Philips, Hemeo utilizes algorithms and a coagulation model enriched with patient data to create a digital coagulation twin for each patient. This digital twin enables clinicians to predict bleeding and thrombosis risks early and administer personalized treatments.

Hemeo is expanding its portfolio of software solutions dedicated to aiding clinicians in life-saving decisions. Additionally, our AI-powered model supports and accelerates medical device and drug research.

The Hemeo Coagulation model incorporates over 100 parameters. Experience our online demo and click "Request Access" below the video to simulate and explore further.

For more details, please visit the Hemeo website or contact r.corlin@hemeo.health.